Friday, October 17, 2008
St. Louis Business Journal
Pfizer Inc. said Friday that it reached agreements that should resolve substantially all of the personal injury, consumer fraud and state attorneys general claims involving its pain medication Bextra. Claims regarding pain medication Celebrex also will be resolved as part of the settlement, the drug company said.
Pfizer withdrew Bextra, a non-steroidal anti-inflammatory (NSAID), from the U.S. market in 2005. Celebrex is still on the market and has not been linked to any significant safety risks, the company said. More…